What is Hemochromatosis?
Hemochromatosis is treated with 12 medications in our database, including Deferasirox, Deferasorox, Deferasirox oral, Exjade, TERUFLEX BLOOD with Diversion Blood Sampling Arm 70 mL CPDA-1, and 7 more. 9 of these have manufacturer assistance programs available to help reduce out-of-pocket costs. Medications are manufactured by Novartis, Terumo, Chiesi. Patients and caregivers can find copay cards, patient assistance programs, and travel grants for Hemochromatosis treatment below.
- Inheritance
- Variable
- Can be inherited in different ways depending on the underlying gene
- Age of Onset
- Variable
- Can begin at different ages, from infancy through adulthood
FDA & Trial Timeline
1 eventNational Institutes of Health Clinical Center (CC) — PHASE2
Data is compiled from FDA regulatory filings and ClinicalTrials.gov, then processed through automated extraction; event classifications and dates may occasionally be misclassified. Verify against the linked FDA filing or trial record before clinical decisions. Updated periodically.
Treatments
0 FDA-approved · 9 other trackedSource: openFDA + DailyMed · NDA / BLA labels with structured indications · refreshed weekly
Other tracked therapies (9)
Medications tracked in our therapeutics database that are not FDA-approved for Hemochromatosis via a labelled indication. May include investigational, off-label, or supportive therapies. Always verify with a clinician before use.
DEFERASIROX
Detailed copay and financial assistance information is not publicly available for this medication at this time. Please consult your pharmacist or the manufacturer's official patient support program fo
Jadenu
* Patient Copay Amount: $0 (Medications are provided free of cost to eligible patients) * Maximum Annual Benefit Limit: Not Publicly Available * Core Eligibility Restrictions: Must reside in the Unite
Deferiprone
Detailed copay and financial assistance information is not publicly available for this medication at this time. Please consult your pharmacist or the manufacturer's official patient support program fo
Deferoxamine
Detailed copay and financial assistance information is not publicly available for this medication at this time. Please consult your pharmacist or the manufacturer's official patient support program fo
TERUFLEX BLOOD with Diversion Blood Sampling Arm 70 mL CPDA-1
Detailed copay and financial assistance information is not publicly available for this medication at this time. Please consult your pharmacist or the manufacturer's official patient support program fo
Deferasirox oral
Detailed copay and financial assistance information is not publicly available for this medication at this time. Please consult your pharmacist or the manufacturer's official patient support program fo
Deferasorox
* Patient Copay Amount: $0 (Medications are provided free of cost to eligible patients) * Maximum Annual Benefit Limit: Not Publicly Available * Core Eligibility Restrictions: Must reside in the Unite
Exjade
Detailed copay and financial assistance information is not publicly available for this medication at this time. Please consult your pharmacist or the manufacturer's official patient support program fo
Deferasirox Oral Granules
* Patient Copay Amount: Not Publicly Available * Maximum Annual Benefit Limit: Not Publicly Available * Core Eligibility Restrictions: Not Publicly Available * RxBIN, PCN, and Group numbers: Not Publi
Source: ClinicalTrials.gov · synced daily · phases, status, and PI names normalized at ingest
Source: NPI Registry + PubMed · trial PI roles cross-referenced with ClinicalTrials.gov · ranked by match score (publications + PI activity + community signal)
Specialty unconfirmed
University of North Carolina
Specialty unconfirmed
University of North Carolina
Specialty unconfirmed
Western University
Specialty unconfirmed
University of Verona and Azienda Ospedaliera Universitaria Integrata Verona
Specialty unconfirmed
University of Verona and Azienda Ospedaliera Universitaria Integrata Verona
Specialty unconfirmed
Beaumont Hospital
Specialty unconfirmed
University of North Carolina
Specialty unconfirmed
Mayo Clinic Florida
Specialty unconfirmed
Mayo Clinic Florida
Specialty unconfirmed
Fiona Stanley Fremantle Hospital Group
Specialty unconfirmed
Fiona Stanley Fremantle Hospital Group
Specialty unconfirmed
Northwestern University Feinberg School of Medicine
Specialty unconfirmed
Hospital Clinic
Specialty unconfirmed
University of Texas Southwestern Medical Center
Specialty unconfirmed
University of Verona and EuroBloodNet Referral Center for Iron Disorders
Rare Disease Specialist
National Institutes of Health Clinical Center
Treatment Centers
8 centersSource: NORD Rare Disease Centers + NIH Undiagnosed Diseases Network (UDN) · centers verified active within last 12 months
National Institutes of Health Clinical Center
📍 Bethesda, Maryland
👤 Payal P Khincha, M.D.
👤 Christopher Grunseich, M.D.
UCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDBoston Children's Hospital Rare Disease Program ↗
Boston Children's Hospital
📍 Boston, MA
👤 Boston Children's Hospital Rare Disease Program
🏨 Children'sChildren's Hospital Colorado Rare Disease Program ↗
Children's Hospital Colorado
📍 Aurora, CO
👤 Boston Children's Hospital Rare Disease Program
🏨 Children'sAnn & Robert H. Lurie Children's Hospital Genetics ↗
Lurie Children's Hospital
📍 Chicago, IL
👤 Boston Children's Hospital Rare Disease Program
🏥 NORDCincinnati Children's Hospital Medical Center ↗
Cincinnati Children's
📍 Cincinnati, OH
👤 Boston Children's Hospital Rare Disease Program
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
Travel Grants
No travel grants are currently matched to Hemochromatosis.
Community
No community posts yet. Be the first to share your experience with Hemochromatosis.
Start the conversation →Latest news about Hemochromatosis
Source: PubMed + NIH RePORTER + openFDA + clinical-journal RSS · last 30 days · disease-tagged at ingest by AI extraction with human QC
Disease timeline:
New trial: Treatment of Hemochromatosis
Phase PHASE2 trial recruiting. Phlebotomy
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Hemochromatosis
What is Hemochromatosis?
Hemochromatosis is treated with 12 medications in our database, including Deferasirox, Deferasorox, Deferasirox oral, Exjade, TERUFLEX BLOOD with Diversion Blood Sampling Arm 70 mL CPDA-1, and 7 more. 9 of these have manufacturer assistance programs available to help reduce out-of-pocket costs. Medications are manufactured by Novartis, Terumo, Chiesi. Patients and caregivers can find copay cards, patient assistance programs, and travel grants for Hemochromatosis treatment below.
Are there clinical trials for Hemochromatosis?
Yes — 1 recruiting clinical trial is currently listed for Hemochromatosis on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Hemochromatosis?
16 specialists and care centers treating Hemochromatosis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.
What treatment and support options exist for Hemochromatosis?
9 FDA-approved treatments and 2 patient support programs are currently tracked on UniteRare for Hemochromatosis. See the treatments and support programs sections for copay assistance, eligibility, and contact details.
Frequently asked questions about Hemochromatosis
Auto-generated from canonical disease facts (Orphanet, OMIM, ClinicalTrials.gov, openFDA, NPPES). Not a substitute for clinical guidance.
What is Hemochromatosis?
Hemochromatosis is a rare disease catalogued in international rare-disease ontologies. It is typically inherited as variable. Age of onset is generally variable. For verified primary sources, see the UniteRare Hemochromatosis page.
How is Hemochromatosis inherited?
Hemochromatosis follows variable inheritance. Genetic counseling is recommended for affected families to understand recurrence risk in offspring and the likelihood of unaffected siblings being carriers. Variants in the underlying gene(s) may be identified via clinical genetic testing.
Are there FDA-approved treatments for Hemochromatosis?
Yes — UniteRare tracks 9 FDA-approved treatments with indications relevant to Hemochromatosis. Each entry includes prescribing information, orphan-drug-designation status where applicable, and the FDA application number for verification.
Are there clinical trials recruiting for Hemochromatosis?
UniteRare currently lists 1 clinical trial relevant to Hemochromatosis sourced from ClinicalTrials.gov. Each trial entry includes recruitment status, eligibility criteria summary, principal-investigator information, and study locations. Patients should discuss eligibility with their healthcare provider before enrolling.
How do I find a specialist for Hemochromatosis?
UniteRare lists 16 verified clinicians with documented expertise in Hemochromatosis, sourced from ClinicalTrials.gov principal-investigator records, PubMed publication histories, and the NPPES NPI registry. Filter by state or browse our state-specific specialist pages for nearby options.
See full Hemochromatosis page for complete clinical details, sources, and verified-specialist listings.
Cite this page
Select a citation format above to view and copy.